Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of ranibizumab, aflibercept, and bevacizumab for macular oedema due to central retinal vein occlusion
2014-000272-26Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Jun 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal vein occlusion (CRVO) comparing Lucentis arm, Eylea arm and Avastin arm (3 arms). Primary endpoint: Change in mean best corrected visual acuity from baseline to 100 weeks. Started Jun 2014; status: completed.
02
Drugs
ranibizumabafliberceptbevacizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2014-000272-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000272-26.